The HER2 biomarker is a predictive prognostic indicator for the evolution of neo-plastic disease, which gives it an augmented aggressiveness, marked in the results of our study by the reduction in the disease-free interval (DFI) and by the occurrence of relapses or by the evolution of metastatic disease. This evidence concerns the gene ERBB2 and metastatic neoplasm.